X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DIVIS LABORATORIES - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DIVIS LABORATORIES IPCA LABS/
DIVIS LABORATORIES
 
P/E (TTM) x 45.0 30.0 150.0% View Chart
P/BV x 3.5 5.2 66.4% View Chart
Dividend Yield % 0.1 1.0 15.6%  

Financials

 IPCA LABS   DIVIS LABORATORIES
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DIVIS LABORATORIES
Mar-17
IPCA LABS/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6431,222 52.6%   
Low Rs503784 64.1%   
Sales per share (Unadj.) Rs254.4153.1 166.2%  
Earnings per share (Unadj.) Rs16.139.9 40.2%  
Cash flow per share (Unadj.) Rs29.844.6 66.8%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.21.0 17.5%  
Book value per share (Unadj.) Rs194.6201.8 96.4%  
Shares outstanding (eoy) m126.20265.47 47.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.36.6 34.4%   
Avg P/E ratio x35.725.1 142.0%  
P/CF ratio (eoy) x19.222.5 85.5%  
Price / Book Value ratio x2.95.0 59.2%  
Dividend payout %6.225.0 24.9%   
Avg Mkt Cap Rs m72,300266,266 27.2%   
No. of employees `00013.39.7 136.7%   
Total wages/salary Rs m6,9604,687 148.5%   
Avg. sales/employee Rs Th2,413.54,175.0 57.8%   
Avg. wages/employee Rs Th523.2481.5 108.7%   
Avg. net profit/employee Rs Th152.41,089.3 14.0%   
INCOME DATA
Net Sales Rs m32,10640,643 79.0%  
Other income Rs m226749 30.1%   
Total revenues Rs m32,33241,392 78.1%   
Gross profit Rs m4,44814,460 30.8%  
Depreciation Rs m1,7301,233 140.2%   
Interest Rs m24123 1,065.5%   
Profit before tax Rs m2,70313,953 19.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6753,349 20.2%   
Profit after tax Rs m2,02810,604 19.1%  
Gross profit margin %13.935.6 38.9%  
Effective tax rate %25.024.0 104.1%   
Net profit margin %6.326.1 24.2%  
BALANCE SHEET DATA
Current assets Rs m17,34040,105 43.2%   
Current liabilities Rs m9,5596,595 145.0%   
Net working cap to sales %24.282.5 29.4%  
Current ratio x1.86.1 29.8%  
Inventory Days Days100119 84.6%  
Debtors Days Days5781 70.5%  
Net fixed assets Rs m20,77919,995 103.9%   
Share capital Rs m252531 47.5%   
"Free" reserves Rs m24,49953,043 46.2%   
Net worth Rs m24,55353,574 45.8%   
Long term debt Rs m3,5170-   
Total assets Rs m39,59561,585 64.3%  
Interest coverage x12.2618.4 2.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.7 122.9%   
Return on assets %5.717.3 33.2%  
Return on equity %8.319.8 41.7%  
Return on capital %10.526.1 40.2%  
Exports to sales %48.60-   
Imports to sales %14.225.2 56.4%   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,57110,259 44.6%   
Fx inflow Rs m15,61735,384 44.1%   
Fx outflow Rs m5,82810,399 56.0%   
Net fx Rs m9,79024,985 39.2%   
CASH FLOW
From Operations Rs m2,76411,493 24.1%  
From Investments Rs m-1,432-11,372 12.6%  
From Financial Activity Rs m-1,591-93 1,709.2%  
Net Cashflow Rs m-25928 -911.3%  

Share Holding

Indian Promoters % 45.9 52.0 88.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 11.8 96.6%  
FIIs % 25.3 19.0 133.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.2 101.2%  
Shareholders   36,892 31,796 116.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  MERCK LTD  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 23, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - FDC LTD. COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS